People who quit taking anti-obesity meds, including popular GLP-1 receptor agonists, may regain a significant amount of weight after eight weeks, a new study finds.

Patients with obesity who take GLP-1 receptor agonists in real-world settings lose significantly less weight than participants in randomized clinical trials, according to new research.

Overweight and obese adults who followed a 4:3 intermittent fasting plan dropped more pounds in one year than those who counted calories.

Hollow cheeks and sagging skin are driving more weight-loss patients to the plastic surgeon; a new survey finds.

A new study finds calorie labels make a small but potentially significant impact on food selection and calorie intake.

U.S. News & World Report, working with leading medical and nutrition experts, reveals a list of the best diets for overall health and specific conditions.

New study examines U.S. trends in body mass index and obesity and finds improving numbers, driven in part by GLP-1 weight-loss drugs.

New research shows GLP-1 agonists, like Ozempic, and SGLT2 inhibitors, like Farxiga, help lower the risk of secondary stroke, heart attack and death in stroke survivors.

Researchers find no link between semaglutide, the main ingredient in Ozempic and Wegovy, and depression, suicidal thoughts or behaviors in patients with no prior history of the conditions.